Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Leukemia. 2018 Mar 23. doi: 10.1038/s41375-018-0107-z. [Epub ahead of print]

PMID:
29654267
2.

Diagnosing MRI-negative autoimmune diseases.

Finke C.

Neurol Neuroimmunol Neuroinflamm. 2018 Apr 2;5(3):e457. doi: 10.1212/NXI.0000000000000457. eCollection 2018 May. No abstract available.

3.

Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.

Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM.

Leuk Lymphoma. 2018 Mar 27:1-4. doi: 10.1080/10428194.2018.1452212. [Epub ahead of print] No abstract available.

PMID:
29582697
4.

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.

Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Leukemia. 2018 Feb 27. doi: 10.1038/s41375-018-0078-0. [Epub ahead of print] No abstract available.

PMID:
29535431
5.

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms.

Lasho TL, Vallapureddy R, Finke CM, Mangaonkar A, Gangat N, Ketterling R, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Mar 12;8(3):32. doi: 10.1038/s41408-018-0057-8. No abstract available.

6.

U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates.

Tefferi A, Mudireddy M, Finke CM, Nicolosi M, Lasho TL, Hanson CA, Patnaik MM, Pardanani A, Gangat N.

Am J Hematol. 2018 Mar 8. doi: 10.1002/ajh.25084. [Epub ahead of print] No abstract available.

PMID:
29516544
7.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

8.

Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.

Jaeger S, Paul F, Scheel M, Brandt A, Heine J, Pach D, Witt CM, Bellmann-Strobl J, Finke C.

Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911. [Epub ahead of print]

9.

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Szuber N, Finke CM, Lasho TL, Elliott MA, Hanson CA, Pardanani A, Tefferi A.

Blood Cancer J. 2018 Feb 15;8(2):21. doi: 10.1038/s41408-018-0058-7. No abstract available.

10.

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.

Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, Litzow MR, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Feb 12;8(2):18. doi: 10.1038/s41408-018-0051-1. No abstract available.

11.

Mayo CALR mutation type classification guide using alpha helix propensity.

Lasho TL, Finke CM, Tischer A, Pardanani A, Tefferi A.

Am J Hematol. 2018 May;93(5):E128-E129. doi: 10.1002/ajh.25065. Epub 2018 Feb 24. No abstract available.

PMID:
29424450
12.

Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.

Gangat N, Mudireddy M, Lasho TL, Finke CM, Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 May;93(5):691-697. doi: 10.1002/ajh.25064. Epub 2018 Feb 24.

PMID:
29417633
13.

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental.

Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, Hanson C, Gangat N, Tefferi A.

Blood Cancer J. 2018 Jan 22;8(1):12. doi: 10.1038/s41408-017-0045-4. No abstract available.

14.

Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis.

Backner Y, Kuchling J, Massarwa S, Oberwahrenbrock T, Finke C, Bellmann-Strobl J, Ruprecht K, Brandt AU, Zimmermann H, Raz N, Paul F, Levin N.

JAMA Neurol. 2018 Mar 1;75(3):287-295. doi: 10.1001/jamaneurol.2017.3880.

PMID:
29297053
15.

Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization.

Finke C, Zimmermann H, Pache F, Oertel FC, Chavarro VS, Kramarenko Y, Bellmann-Strobl J, Ruprecht K, Brandt AU, Paul F.

JAMA Neurol. 2018 Mar 1;75(3):296-303. doi: 10.1001/jamaneurol.2017.3890.

PMID:
29297041
16.

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.

Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2017 Dec 27;7(12):662. doi: 10.1038/s41408-017-0035-6.

17.

Pursuing functional connectivity in NMDAR1 autoantibody carriers - Authors' reply.

Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C.

Lancet Psychiatry. 2018 Jan;5(1):22. doi: 10.1016/S2215-0366(17)30488-1. No abstract available.

PMID:
29277209
18.

JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease.

Tefferi A, Lavu S, Mudireddy M, Lasho TL, Finke CM, Gangat N, Pardanani A, Hanson CA, Mannarelli C, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2018 Aug;93(4):E93-E96. doi: 10.1002/ajh.25017. No abstract available.

19.

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).

Tefferi A, Idossa D, Lasho TL, Mudireddy M, Finke C, Shah S, Nicolosi M, Patnaik MM, Pardanani A, Gangat N, Hanson CA, Ketterling RP.

Blood Cancer J. 2017 Dec 18;7(12):658. doi: 10.1038/s41408-017-0017-8. No abstract available.

20.

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2018 Mar;93(3):348-355. doi: 10.1002/ajh.24978. Epub 2017 Dec 18.

PMID:
29164670
21.

Superficial white matter damage in anti-NMDA receptor encephalitis.

Phillips OR, Joshi SH, Narr KL, Shattuck DW, Singh M, Di Paola M, Ploner CJ, Prüss H, Paul F, Finke C.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):518-525. doi: 10.1136/jnnp-2017-316822. Epub 2017 Nov 3.

PMID:
29101253
22.

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis.

Tefferi A, Lasho TL, Finke C, Gangat N, Hanson CA, Ketterling RP, Pardanani A.

Leukemia. 2018 Mar;32(3):837-839. doi: 10.1038/leu.2017.318. Epub 2017 Nov 1. No abstract available.

PMID:
29089644
23.

Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.

Patnaik MM, Vallapureddy R, Yalniz FF, Hanson CA, Ketterling RP, Lasho TL, Finke C, Al-Kali A, Gangat N, Tefferi A.

Am J Hematol. 2018 Jan;93(1):65-73. doi: 10.1002/ajh.24939. Epub 2017 Nov 3.

PMID:
29023992
24.

Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study.

Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C.

Lancet Psychiatry. 2017 Oct;4(10):768-774. doi: 10.1016/S2215-0366(17)30330-9. Epub 2017 Sep 4.

PMID:
28882707
25.

Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.

Tefferi A, Lasho TL, Patnaik MM, Saeed L, Mudireddy M, Idossa D, Finke C, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2017 Dec;92(12):1311-1317. doi: 10.1002/ajh.24901. Epub 2017 Oct 20.

PMID:
28875545
26.

Oral manifestations, dental management, and a rare homozygous mutation of the PRDM12 gene in a boy with hereditary sensory and autonomic neuropathy type VIII: a case report and review of the literature.

Elhennawy K, Reda S, Finke C, Graul-Neumann L, Jost-Brinkmann PG, Bartzela T.

J Med Case Rep. 2017 Aug 15;11(1):233. doi: 10.1186/s13256-017-1387-z.

27.

High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.

Finke C, Bartels F, Lütt A, Prüss H, Harms L.

J Neurol. 2017 Sep;264(9):1968-1977. doi: 10.1007/s00415-017-8582-0. Epub 2017 Aug 7.

PMID:
28785798
28.

Memory integration in humans with hippocampal lesions.

Pajkert A, Finke C, Shing YL, Hoffmann M, Sommer W, Heekeren HR, Ploner CJ.

Hippocampus. 2017 Dec;27(12):1230-1238. doi: 10.1002/hipo.22766. Epub 2017 Aug 9.

PMID:
28768057
29.

Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance.

Vallapureddy R, Lasho TL, Hoversten K, Finke CM, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM.

Am J Hematol. 2017 Oct;92(10):E614-E618. doi: 10.1002/ajh.24861. Epub 2017 Jul 29. No abstract available.

PMID:
28707414
30.

Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review.

McKeon GL, Robinson GA, Ryan AE, Blum S, Gillis D, Finke C, Scott JG.

J Clin Exp Neuropsychol. 2018 Apr;40(3):234-252. doi: 10.1080/13803395.2017.1329408. Epub 2017 Jun 6.

PMID:
28585453
31.

Monocytosis in polycythemia vera: Clinical and molecular correlates.

Barraco D, Cerquozzi S, Gangat N, Patnaik MM, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.

Am J Hematol. 2017 Jul;92(7):640-645. doi: 10.1002/ajh.24740. Epub 2017 May 26.

PMID:
28370365
32.

Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.

Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, Ketterling RP, Gangat N, Tefferi A.

Am J Hematol. 2017 Jun;92(6):542-548. doi: 10.1002/ajh.24722. Epub 2017 Apr 29.

PMID:
28314085
33.

Targeted deep sequencing in primary myelofibrosis.

Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Blood Adv. 2016 Nov 30;1(2):105-111. doi: 10.1182/bloodadvances.2016000208. eCollection 2016 Dec 13.

34.

Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies.

Finke C, Prüss H, Heine J, Reuter S, Kopp UA, Wegner F, Then Bergh F, Koch S, Jansen O, Münte T, Deuschl G, Ruprecht K, Stöcker W, Wandinger KP, Paul F, Bartsch T.

JAMA Neurol. 2017 Jan 1;74(1):50-59. doi: 10.1001/jamaneurol.2016.4226.

PMID:
27893017
35.

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, Pacilli A, Hanson CA, Pancrazzi A, Ketterling RP, Mannarelli C, Barraco D, Fanelli T, Pardanani A, Gangat N, Vannucchi AM.

Blood Adv. 2016 Nov 22;1(1):21-30. doi: 10.1182/bloodadvances.2016000216. eCollection 2016 Nov 29.

36.

Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis.

Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A.

Leukemia. 2016 Nov;30(11):2273-2275. doi: 10.1038/leu.2016.216. Epub 2016 Aug 1. No abstract available.

PMID:
27479179
37.

ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis.

Pardanani AD, Lasho TL, Finke C, Zblewski DL, Abdelrahman RA, Wassie EA, Gangat N, Hanson CA, Ketterling RP, Tefferi A.

Br J Haematol. 2016 Nov;175(3):534-536. doi: 10.1111/bjh.13865. Epub 2015 Dec 2. No abstract available.

PMID:
26628266
38.

Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia.

Zahid MF, Barraco D, Lasho TL, Finke C, Ketterling RP, Gangat N, Hanson CA, Tefferi A, Patnaik MM.

Leuk Lymphoma. 2017 Jun;58(6):1488-1493. doi: 10.1080/10428194.2016.1243681. Epub 2016 Oct 14. No abstract available.

PMID:
27739921
39.

DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.

Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Gangat N, Tefferi A.

Am J Hematol. 2017 Jan;92(1):56-61. doi: 10.1002/ajh.24581. Epub 2016 Dec 7.

40.

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance.

Patnaik MM, Zahid MF, Lasho TL, Finke C, Ketterling RL, Gangat N, Robertson KD, Hanson CA, Tefferi A.

Blood Cancer J. 2016 Sep 23;6(9):e472. doi: 10.1038/bcj.2016.82. No abstract available.

41.

Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study.

Heine J, Ly LT, Lieker I, Slowinski T, Finke C, Prüss H, Harms L.

J Neurol. 2016 Dec;263(12):2395-2402. Epub 2016 Sep 7.

PMID:
27604620
42.

Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis.

Barraco D, Lasho TL, Gangat N, Finke C, Elala YC, Pardanani A, Tefferi A.

Blood Cancer J. 2016 Jun 17;6:e436. doi: 10.1038/bcj.2016.44. No abstract available.

43.

Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.

Pardanani A, Lasho T, Elala Y, Wassie E, Finke C, Reichard KK, Chen D, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2016 Sep;91(9):888-93. doi: 10.1002/ajh.24426. Epub 2016 Jun 20.

44.

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.

Barraco D, Elala YC, Lasho TL, Begna KH, Gangat N, Finke C, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.

Blood Cancer J. 2016 May 6;6:e416. doi: 10.1038/bcj.2016.24. No abstract available.

45.

Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD.

Finke C, Heine J, Pache F, Lacheta A, Borisow N, Kuchling J, Bellmann-Strobl J, Ruprecht K, Brandt AU, Paul F.

Neurol Neuroimmunol Neuroinflamm. 2016 Apr 20;3(3):e229. doi: 10.1212/NXI.0000000000000229. eCollection 2016 Jun.

46.

Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing.

Pardanani A, Lasho T, Wassie E, Finke C, Zblewski D, Hanson CA, Ketterling RP, Gangat N, Tefferi A.

Leukemia. 2016 Sep;30(9):1924-6. doi: 10.1038/leu.2016.73. Epub 2016 Apr 5. No abstract available.

PMID:
27125206
47.

Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors.

Vaa BE, Tefferi A, Gangat N, Pardanani A, Lasho TL, Finke CM, Wolanskyj AP.

Ann Hematol. 2016 Jun;95(7):1185-9. doi: 10.1007/s00277-016-2674-2. Epub 2016 Apr 23.

PMID:
27106700
48.

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.

Barraco D, Elala YC, Lasho TL, Begna KH, Gangat N, Finke C, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.

Blood Cancer J. 2016 Apr 8;6:e415. doi: 10.1038/bcj.2016.22. No abstract available. Erratum in: Blood Cancer J. 2016 May 06;6:e416.

49.

Effects of Anti-NMDA Antibodies on Functional Recovery and Synaptic Rearrangement Following Hemicerebellectomy.

Laricchiuta D, Cavallucci V, Cutuli D, De Bartolo P, Caporali P, Foti F, Finke C, D'Amelio M, Manto M, Petrosini L.

Neuromolecular Med. 2016 Jun;18(2):190-202. doi: 10.1007/s12017-016-8390-1. Epub 2016 Mar 30.

PMID:
27027521
50.

Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study.

Pache F, Zimmermann H, Finke C, Lacheta A, Papazoglou S, Kuchling J, Wuerfel J, Hamm B, Ruprecht K, Paul F, Brandt AU, Scheel M.

Eur Radiol. 2016 Dec;26(12):4413-4422. Epub 2016 Mar 24.

PMID:
27012555

Supplemental Content

Support Center